vs

Side-by-side financial comparison of KRONOS WORLDWIDE INC (KRO) and MYRIAD GENETICS INC (MYGN). Click either name above to swap in a different company.

KRONOS WORLDWIDE INC is the larger business by last-quarter revenue ($418.3M vs $209.8M, roughly 2.0× MYRIAD GENETICS INC). On growth, MYRIAD GENETICS INC posted the faster year-over-year revenue change (-0.4% vs -1.1%). Over the past eight quarters, MYRIAD GENETICS INC's revenue compounded faster (1.9% CAGR vs -6.5%).

Kronos Incorporated was an American multinational workforce management and human capital management cloud provider headquartered in Lowell, Massachusetts, United States, which employed more than 6,000 people worldwide.

Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a pati...

KRO vs MYGN — Head-to-Head

Bigger by revenue
KRO
KRO
2.0× larger
KRO
$418.3M
$209.8M
MYGN
Growing faster (revenue YoY)
MYGN
MYGN
+0.8% gap
MYGN
-0.4%
-1.1%
KRO
Faster 2-yr revenue CAGR
MYGN
MYGN
Annualised
MYGN
1.9%
-6.5%
KRO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
KRO
KRO
MYGN
MYGN
Revenue
$418.3M
$209.8M
Net Profit
$-82.8M
Gross Margin
-0.9%
70.0%
Operating Margin
-15.1%
-2.7%
Net Margin
-19.8%
Revenue YoY
-1.1%
-0.4%
Net Profit YoY
-527.3%
EPS (diluted)
$-0.72
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
KRO
KRO
MYGN
MYGN
Q4 25
$418.3M
$209.8M
Q3 25
$456.9M
$205.7M
Q2 25
$494.4M
$213.1M
Q1 25
$489.8M
$195.9M
Q4 24
$423.1M
$210.6M
Q3 24
$484.7M
$213.3M
Q2 24
$500.5M
$211.5M
Q1 24
$478.8M
$202.2M
Net Profit
KRO
KRO
MYGN
MYGN
Q4 25
$-82.8M
Q3 25
$-37.0M
$-27.4M
Q2 25
$-9.2M
$-330.5M
Q1 25
$18.1M
$-100.0K
Q4 24
$-13.2M
Q3 24
$71.8M
$-22.1M
Q2 24
$19.5M
$-36.7M
Q1 24
$8.1M
$-26.0M
Gross Margin
KRO
KRO
MYGN
MYGN
Q4 25
-0.9%
70.0%
Q3 25
10.3%
69.9%
Q2 25
12.7%
71.2%
Q1 25
21.8%
68.5%
Q4 24
20.4%
71.7%
Q3 24
20.9%
70.2%
Q2 24
20.0%
69.6%
Q1 24
14.9%
68.1%
Operating Margin
KRO
KRO
MYGN
MYGN
Q4 25
-15.1%
-2.7%
Q3 25
-4.2%
-11.3%
Q2 25
1.5%
-154.5%
Q1 25
7.8%
-14.8%
Q4 24
6.8%
-18.6%
Q3 24
8.0%
-9.4%
Q2 24
7.2%
-17.3%
Q1 24
4.1%
-13.8%
Net Margin
KRO
KRO
MYGN
MYGN
Q4 25
-19.8%
Q3 25
-8.1%
-13.3%
Q2 25
-1.9%
-155.1%
Q1 25
3.7%
-0.1%
Q4 24
-3.1%
Q3 24
14.8%
-10.4%
Q2 24
3.9%
-17.4%
Q1 24
1.7%
-12.9%
EPS (diluted)
KRO
KRO
MYGN
MYGN
Q4 25
$-0.72
$-0.09
Q3 25
$-0.32
$-0.29
Q2 25
$-0.08
$-3.57
Q1 25
$0.16
$0.00
Q4 24
$-0.11
$-0.47
Q3 24
$0.62
$-0.24
Q2 24
$0.17
$-0.41
Q1 24
$0.07
$-0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
KRO
KRO
MYGN
MYGN
Cash + ST InvestmentsLiquidity on hand
$33.2M
$149.6M
Total DebtLower is stronger
$557.4M
$119.9M
Stockholders' EquityBook value
$751.1M
$368.0M
Total Assets
$1.8B
$706.6M
Debt / EquityLower = less leverage
0.74×
0.33×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
KRO
KRO
MYGN
MYGN
Q4 25
$33.2M
$149.6M
Q3 25
$27.7M
$145.4M
Q2 25
$18.9M
$74.4M
Q1 25
$20.5M
$91.8M
Q4 24
$106.7M
$102.4M
Q3 24
$94.8M
$99.9M
Q2 24
$133.8M
$97.3M
Q1 24
$120.7M
$104.3M
Total Debt
KRO
KRO
MYGN
MYGN
Q4 25
$557.4M
$119.9M
Q3 25
$626.2M
$119.5M
Q2 25
$589.3M
Q1 25
$557.2M
Q4 24
$507.4M
Q3 24
$554.3M
Q2 24
$423.7M
Q1 24
$426.9M
Stockholders' Equity
KRO
KRO
MYGN
MYGN
Q4 25
$751.1M
$368.0M
Q3 25
$804.7M
$372.8M
Q2 25
$846.8M
$388.1M
Q1 25
$847.0M
$704.9M
Q4 24
$817.0M
$701.1M
Q3 24
$847.4M
$731.7M
Q2 24
$774.6M
$740.5M
Q1 24
$774.4M
$760.0M
Total Assets
KRO
KRO
MYGN
MYGN
Q4 25
$1.8B
$706.6M
Q3 25
$1.9B
$728.1M
Q2 25
$1.9B
$677.3M
Q1 25
$1.9B
$1.0B
Q4 24
$1.9B
$1.0B
Q3 24
$1.9B
$1.1B
Q2 24
$1.7B
$1.1B
Q1 24
$1.7B
$1.1B
Debt / Equity
KRO
KRO
MYGN
MYGN
Q4 25
0.74×
0.33×
Q3 25
0.78×
0.32×
Q2 25
0.70×
Q1 25
0.66×
Q4 24
0.62×
Q3 24
0.65×
Q2 24
0.55×
Q1 24
0.55×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
KRO
KRO
MYGN
MYGN
Operating Cash FlowLast quarter
$92.1M
$10.6M
Free Cash FlowOCF − Capex
$81.9M
FCF MarginFCF / Revenue
19.6%
Capex IntensityCapex / Revenue
2.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-40.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
KRO
KRO
MYGN
MYGN
Q4 25
$92.1M
$10.6M
Q3 25
$-7.9M
$21.1M
Q2 25
$20.7M
$-13.6M
Q1 25
$-102.4M
$-16.3M
Q4 24
$49.3M
$6.6M
Q3 24
$28.3M
$700.0K
Q2 24
$38.2M
$2.6M
Q1 24
$-43.3M
$-18.6M
Free Cash Flow
KRO
KRO
MYGN
MYGN
Q4 25
$81.9M
Q3 25
$-17.4M
Q2 25
$9.5M
Q1 25
$-114.4M
Q4 24
$37.0M
Q3 24
$19.2M
Q2 24
$34.8M
Q1 24
$-48.0M
FCF Margin
KRO
KRO
MYGN
MYGN
Q4 25
19.6%
Q3 25
-3.8%
Q2 25
1.9%
Q1 25
-23.4%
Q4 24
8.7%
Q3 24
4.0%
Q2 24
7.0%
Q1 24
-10.0%
Capex Intensity
KRO
KRO
MYGN
MYGN
Q4 25
2.4%
Q3 25
2.1%
Q2 25
2.3%
Q1 25
2.4%
Q4 24
2.9%
Q3 24
1.9%
Q2 24
0.7%
Q1 24
1.0%
Cash Conversion
KRO
KRO
MYGN
MYGN
Q4 25
Q3 25
Q2 25
Q1 25
-5.66×
Q4 24
Q3 24
0.39×
Q2 24
1.96×
Q1 24
-5.35×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons